Dosing & Uses
Dosage Forms & Strengths
intravenous solution
- 1mg/2mL (0.5mg/mL)
Breast Cancer, Metastatic
Indicated for metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease; prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting
1.4 mg/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle
Liposarcoma
Indicated for unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen
1.4 mg/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle
Dosage Modifications
Assess for peripheral neuropathy and obtain CBC counts prior to each dose
Recommended dose delays
Do not administer on Day 1 or Day 8 for any of the following
- ANC <1,000/mm³
- Platelets <75,000/mm³
- Grade 3 or 4 nonhematological toxicities
The Day 8 dose may be delayed for a maximum of 1 week:
- If toxicities do not resolve or improve to ≤Grade 2 severity by Day 15, omit the dose
- If toxicities resolve or improved to ≤Grade 2 severity by Day 15, administer at a reduced dose and initiate the next cycle no sooner than 2 weeks later
Recommended dose reductions
- If a dose has been delayed for toxicity and then recovered to ≤Grade 2 severity, resume at reduced doses (see below)
- Do not re-escalate once dose has been reduced
Permanently reduce the 1.4 mg/m² dose to 1.1 mg/m² for any of the following:
- ANC <500/mm³ for >7 days
- ANC <1,000/mm³ with fever or infection
- Platelets <25,000/mm³
- Platelets <50,000/mm³ requiring transfusion
- Nonhematologic Grade 3 or 4 toxicities
- Omission or delay of Day 8 dose in previous cycle for toxicity
Permanently reduce dose to 0.7 mg/m² for any of the following:
- Occurrence of any event requiring permanent dose reduction while receiving 1.1 mg/m²
Discontinue
- Occurrence of any event requiring permanent dose reduction while receiving 0.7 mg/m²
Renal impairment
- Moderate-to-severe (CrCl 15-49 mL/min): 1.1 mg/m² IV
Hepatic impairment
- Mild (Child-Pugh A): 1.1 mg/m² IV
- Moderate (Child-Pugh B): 0.7 mg/m² IV
Safety and efficacy not established
No overall differences in safety were observed between elderly and younger patients
See Adult Dosing section
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (136)
- adagrasib
adagrasib, eribulin. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- alfuzosin
alfuzosin and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- amiodarone
eribulin and amiodarone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- amisulpride
eribulin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- anagrelide
eribulin and anagrelide both increase QTc interval. Avoid or Use Alternate Drug.
- apomorphine
apomorphine and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- aripiprazole
aripiprazole and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- arsenic trioxide
eribulin and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- artemether
eribulin and artemether both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- artemether/lumefantrine
eribulin and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- asenapine
eribulin and asenapine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- asenapine transdermal
asenapine transdermal and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- atomoxetine
eribulin and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.
- bedaquiline
bedaquiline and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine
eribulin and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine buccal
buprenorphine buccal and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine transdermal
buprenorphine transdermal and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- ceritinib
ceritinib and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- chloroquine
eribulin and chloroquine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- chlorpromazine
eribulin and chlorpromazine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- ciprofloxacin
eribulin and ciprofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- citalopram
citalopram and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- clarithromycin
eribulin and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- clozapine
clozapine and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- crizotinib
crizotinib and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- dasatinib
dasatinib and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- degarelix
eribulin and degarelix both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- desflurane
desflurane and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- disopyramide
eribulin and disopyramide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- dofetilide
eribulin and dofetilide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
dofetilide increases toxicity of eribulin by QTc interval. Avoid or Use Alternate Drug. - dolasetron
eribulin and dolasetron both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- donepezil
donepezil and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- dronedarone
eribulin and dronedarone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- droperidol
eribulin and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- efavirenz
efavirenz and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- eliglustat
eribulin and eliglustat both increase QTc interval. Avoid or Use Alternate Drug.
- encorafenib
encorafenib and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
eribulin and encorafenib both increase QTc interval. Avoid or Use Alternate Drug. - entrectinib
eribulin and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin base
eribulin and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- erythromycin ethylsuccinate
eribulin and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- erythromycin lactobionate
eribulin and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- erythromycin stearate
eribulin and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- escitalopram
escitalopram increases toxicity of eribulin by QTc interval. Avoid or Use Alternate Drug.
- fexinidazole
fexinidazole and eribulin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
eribulin and fexinidazole both increase QTc interval. Avoid or Use Alternate Drug. - fingolimod
fingolimod and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- flecainide
eribulin and flecainide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- fluconazole
eribulin and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
- fluvoxamine
eribulin and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.
- foscarnet
eribulin and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.
- gemifloxacin
gemifloxacin and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
eribulin and gemifloxacin both increase QTc interval. Avoid or Use Alternate Drug. - gilteritinib
eribulin and gilteritinib both increase QTc interval. Avoid or Use Alternate Drug.
- glasdegib
eribulin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- granisetron
eribulin and granisetron both increase QTc interval. Avoid or Use Alternate Drug.
- haloperidol
eribulin and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- hydroxyzine
eribulin and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.
- ibutilide
eribulin and ibutilide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- iloperidone
eribulin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- inotuzumab
inotuzumab and eribulin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
- isoflurane
eribulin and isoflurane both increase QTc interval. Avoid or Use Alternate Drug.
- itraconazole
eribulin and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.
- ivosidenib
ivosidenib and eribulin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- lapatinib
eribulin and lapatinib both increase QTc interval. Avoid or Use Alternate Drug.
- lefamulin
lefamulin and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
eribulin and lefamulin both increase QTc interval. Avoid or Use Alternate Drug. - levofloxacin
eribulin and levofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- lithium
eribulin and lithium both increase QTc interval. Avoid or Use Alternate Drug.
- lofexidine
eribulin and lofexidine both increase QTc interval. Avoid or Use Alternate Drug.
- loperamide
eribulin and loperamide both increase QTc interval. Avoid or Use Alternate Drug.
- lopinavir
eribulin and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.
- lumefantrine
eribulin and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- macimorelin
macimorelin and eribulin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- maprotiline
eribulin and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.
- mefloquine
eribulin and mefloquine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- methadone
eribulin and methadone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- midostaurin
eribulin and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.
- mifepristone
eribulin and mifepristone both increase QTc interval. Avoid or Use Alternate Drug.
- mirtazapine
eribulin and mirtazapine both increase QTc interval. Avoid or Use Alternate Drug.
- mobocertinib
mobocertinib and eribulin both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.
- moxifloxacin
eribulin and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- nilotinib
eribulin and nilotinib both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- octreotide
eribulin and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
- ofloxacin
eribulin and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- olanzapine
eribulin and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances
- ondansetron
eribulin and ondansetron both increase QTc interval. Avoid or Use Alternate Drug.
- oxaliplatin
eribulin and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug.
- palifermin
palifermin increases toxicity of eribulin by Other (see comment). Avoid or Use Alternate Drug. Comment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis.
- paliperidone
eribulin and paliperidone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- panobinostat
eribulin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- pasireotide
eribulin and pasireotide both increase QTc interval. Avoid or Use Alternate Drug.
- pazopanib
eribulin and pazopanib both increase QTc interval. Avoid or Use Alternate Drug.
- pentamidine
eribulin and pentamidine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- pimavanserin
eribulin and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug.
- pimozide
eribulin and pimozide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- pitolisant
eribulin and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
- pomalidomide
eribulin increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
- ponesimod
eribulin and ponesimod both increase QTc interval. Avoid or Use Alternate Drug.
- posaconazole
eribulin and posaconazole both increase QTc interval. Avoid or Use Alternate Drug.
- primaquine
eribulin and primaquine both increase QTc interval. Avoid or Use Alternate Drug.
- procainamide
eribulin and procainamide both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- promethazine
eribulin and promethazine both decrease QTc interval. Avoid or Use Alternate Drug.
- propafenone
eribulin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
- quetiapine
eribulin and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.
- quinidine
eribulin and quinidine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- quinine
eribulin and quinine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- ranolazine
eribulin and ranolazine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- ribociclib
ribociclib increases toxicity of eribulin by QTc interval. Avoid or Use Alternate Drug.
- rilpivirine
eribulin and rilpivirine both increase QTc interval. Avoid or Use Alternate Drug.
- romidepsin
eribulin and romidepsin both increase QTc interval. Avoid or Use Alternate Drug.
- ropeginterferon alfa 2b
ropeginterferon alfa 2b, eribulin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.
- saquinavir
eribulin and saquinavir both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- selinexor
selinexor, eribulin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sertraline
eribulin and sertraline both increase QTc interval. Avoid or Use Alternate Drug.
- sevoflurane
eribulin and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug.
- siponimod
eribulin and siponimod both increase QTc interval. Avoid or Use Alternate Drug.
- solifenacin
eribulin and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.
- sorafenib
eribulin and sorafenib both increase QTc interval. Avoid or Use Alternate Drug.
- sotalol
eribulin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- sunitinib
eribulin and sunitinib both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- tacrolimus
eribulin and tacrolimus both increase QTc interval. Avoid or Use Alternate Drug.
- telavancin
eribulin and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- tetrabenazine
eribulin and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- thioridazine
eribulin and thioridazine both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- toremifene
eribulin and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- trazodone
eribulin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- triclabendazole
eribulin and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.
- umeclidinium bromide/vilanterol inhaled
eribulin increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- vandetanib
eribulin and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.
- vardenafil
eribulin and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.
- vemurafenib
eribulin and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.
- venlafaxine
eribulin and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.
- vilanterol/fluticasone furoate inhaled
eribulin increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- voriconazole
eribulin and voriconazole both increase QTc interval. Avoid or Use Alternate Drug.
- vorinostat
eribulin and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.
- ziprasidone
eribulin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
Monitor Closely (46)
- albuterol
albuterol and eribulin both increase QTc interval. Use Caution/Monitor.
- alfuzosin
eribulin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- amitriptyline
eribulin and amitriptyline both increase QTc interval. Use Caution/Monitor.
- arformoterol
arformoterol and eribulin both increase QTc interval. Use Caution/Monitor.
- cholera vaccine
eribulin decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.
- clomipramine
eribulin and clomipramine both increase QTc interval. Use Caution/Monitor.
- dengue vaccine
eribulin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.
- desipramine
eribulin and desipramine both increase QTc interval. Use Caution/Monitor.
- deutetrabenazine
deutetrabenazine and eribulin both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dichlorphenamide
dichlorphenamide and eribulin both decrease serum potassium. Use Caution/Monitor.
- digoxin
eribulin will decrease the level or effect of digoxin by Other (see comment). Use Caution/Monitor. Antineoplastic agents may decrease absorption of digoxin; monitor patients for therapeutic efficacy.
- doxepin
doxepin and eribulin both increase QTc interval. Use Caution/Monitor.
- fingolimod
eribulin increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .
- fluoxetine
eribulin and fluoxetine both increase QTc interval. Use Caution/Monitor.
- fluphenazine
eribulin and fluphenazine both increase QTc interval. Use Caution/Monitor.
- formoterol
eribulin and formoterol both increase QTc interval. Use Caution/Monitor.
- fostemsavir
eribulin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gemtuzumab
eribulin and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- goserelin
goserelin increases toxicity of eribulin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- histrelin
histrelin increases toxicity of eribulin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- imipramine
eribulin and imipramine both increase QTc interval. Use Caution/Monitor.
- indacaterol, inhaled
eribulin and indacaterol, inhaled both increase QTc interval. Use Caution/Monitor.
- lenvatinib
eribulin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- leuprolide
leuprolide increases toxicity of eribulin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- levalbuterol
eribulin and levalbuterol both increase QTc interval. Use Caution/Monitor.
- nortriptyline
eribulin and nortriptyline both increase QTc interval. Use Caution/Monitor.
- olodaterol inhaled
eribulin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.
- osilodrostat
osilodrostat and eribulin both increase QTc interval. Use Caution/Monitor.
- osimertinib
osimertinib and eribulin both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxaliplatin
oxaliplatin will increase the level or effect of eribulin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- ozanimod
ozanimod and eribulin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- perphenazine
eribulin and perphenazine both increase QTc interval. Use Caution/Monitor.
- ponesimod
ponesimod and eribulin both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.
- prochlorperazine
eribulin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- protriptyline
eribulin and protriptyline both increase QTc interval. Use Caution/Monitor.
- quizartinib
quizartinib, eribulin. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
- risperidone
eribulin and risperidone both increase QTc interval. Use Caution/Monitor.
- salmeterol
eribulin and salmeterol both increase QTc interval. Use Caution/Monitor.
- selpercatinib
selpercatinib increases toxicity of eribulin by QTc interval. Use Caution/Monitor.
- siponimod
siponimod and eribulin both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.
- sipuleucel-T
eribulin decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.
- trifluoperazine
eribulin and trifluoperazine both decrease QTc interval. Use Caution/Monitor.
- trimipramine
eribulin and trimipramine both increase QTc interval. Use Caution/Monitor.
- triptorelin
triptorelin increases toxicity of eribulin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- valbenazine
valbenazine and eribulin both increase QTc interval. Use Caution/Monitor.
- voclosporin
voclosporin, eribulin. Either increases effects of the other by QTc interval. Use Caution/Monitor.
Minor (2)
- azithromycin
azithromycin increases toxicity of eribulin by QTc interval. Minor/Significance Unknown.
- chloroquine
chloroquine increases toxicity of eribulin by QTc interval. Minor/Significance Unknown.
Adverse Effects
>10%
Neutropenia (82%)
Anemia (58%)
Asthenia/fatigue (54%)
Alopecia (45%)
Peripheral neuropathy (35%)
Nausea (35%)
Constipation (25%)
Arthralgia/myalgia (22%)
Pyrexia (21%)
Weight loss (21%)
Anorexia (20%)
Headache (19%)
Vomiting (18%)
Diarrhea (18%)
Back pain (16%)
Dyspnea (16%)
Cough (14%)
Bone pain (12%)
Extremity pain (11%)
Urinary tract infection (10%)
1-10%
Increased lacrimation
Dyspepsia
Abdominal pain
Stomatitis
Xerostomia
URI
Hypokalemia
Muscle spasm/weakness
Dysgeusia
Dizziness
Insomnia
Depression
Rash
Postmarketing Reports
Gastrointestinal disorders: Pancreatitis
Blood and lymphatic system disorders: Lymphopenia
Hepatobiliary disorders: Hepatotoxicity
Immune system disorders: Drug hypersensitivity
Infections and infestations: Pneumonia, sepsis/neutropenic sepsis
Metabolism and nutrition disorders: Hypomagnesemia, dehydration
Respiratory, thoracic and mediastinal disorders: Interstitial lung disease
Skin and subcutaneous tissue disorders: Pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis
Warnings
Contraindications
None known
Cautions
Monitor for peripheral neuropathy before each dose (see Dosage Modifications)
Severe neutropenia reported; monitor complete blood counts prior to each dose (see Dosage Modifications); increase frequency of monitoring in patients who develop Grade 3 or 4 cytopenias; delay therapy and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days
Delay administration and/or reduce dose if ANC <1,000/m³, platelets <75,000/m³, or for grade 3-4 nonhematological toxicities (see Dosage Modifications)
Caution with CHF, bradyarrhythmias, and congenital long QT syndrome (monitor for QT prolongation); correct hypokalemia or hypomagnesemia before administering drug
May cause additive effects when coadministration with other drugs that prolong QT interval (eg, class Ia or III antiarrhythmics, thioridazine, erythromycin)
Based on animal studies and its mechanism of action, can cause fetal harm when administered to pregnant women or males with female partners of reproductive potential
Pregnancy & Lactation
Pregnancy
Based on findings from an animal reproduction study and its mechanism of action, can cause fetal harm when administered to a pregnant woman
There are no available data on the use during pregnancy
Animal studies
- In an animal reproduction study, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human
Contraception
- Females: Advise females of reproductive potential to use effective contraception during treatment and for at least 2 weeks following the final dose
- Males: Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3.5 months following the final dose
Infertility
- Based on animal data, may result in damage to male reproductive tissues leading to impaired fertility of unknown duration
Lactation
Unknown whether distributed in breast milk, caution advised; because of the potential for serious adverse reactions in human milk fed infants, a decision should be made whether to discontinue nursing or to discontinue eribulin, taking into account the importance of the drug to the mother
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Microtubule inhibitor; inhibits growth phase of microtubules, leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death
Pharmacokinetics
Half-life elimination: 40 hr
Vd: 43-115 L/m²
Protein Bound: 49-65%
Metabolism: Negligible
Clearance: 1.16-2.42 L/hr
Excretion: Mostly unchanged in feces (82%), urine (9%)
Administration
IV Incompatibilities
Additive: Dextrose
Y-site: Dextrose
IV Compatibilities
Solution: 0.9% NaCl
IV Preparation
Clear, colorless, sterile solution for IV administration
Each vial contains 1 mg of eribulin mesylate as a 0.5 mg/mL solution in ethanol:water (5:95)
IV infusion: Aseptically withdraw dose; may be administered undiluted or diluted (in 0.9% NaCl 100 mL)
Discard unused portion of vial
IV Administration
May be administered undiluted or diluted (in 0.9% NaCl 100 mL)
Administer over 2-5 minutes
Do not dilute in or administer through IV line contain solutions with dextrose
Do not administer in same IV line concurrent with other medical products
Storage
Store undiluted eribulin in syringe for up to 4 hr at room temperature or for up to 24 hr under refrigeration (40°F or/ 4°C)
Store diluted solutions of eribulin for up to 4 hr at room temperature or up to 24 hr under refrigeration (40°F or/ 4°C)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Halaven intravenous - | 1 mg/2 mL (0.5 mg/mL) vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
eribulin intravenous
ERIBULIN - INJECTION
(ER-i-BUE-lin)
COMMON BRAND NAME(S): Halaven
USES: Eribulin is used to treat certain types of cancer (breast, liposarcoma). It works by slowing or stopping the growth of cancer cells.
HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start using eribulin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.This medication is given by injection into a vein by a health care professional. It is given on a schedule as directed by your doctor. The dosage is based on your medical condition, body size, and response to treatment.
SIDE EFFECTS: Nausea, constipation, watering eyes, loss of appetite, dry mouth, changes in taste, trouble sleeping, muscle/joint pain, dizziness, tiredness, or weakness may occur. If any of these effects last or get worse, tell your doctor promptly.Temporary hair loss may occur. Normal hair growth should return after treatment has ended.People using this medication may have serious side effects. However, you have been prescribed this drug because your doctor has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk.Tell your doctor right away if you have any serious side effects, including: easy bruising/bleeding, numbness/tingling/burning in the hands/feet, signs of anemia (such as unusual tiredness, pale skin).This medication can lower the body's ability to fight an infection. Tell your doctor right away if you develop any signs of an infection such as fever, chills, cough, or burning/pain when you urinate.Get medical help right away if you have any very serious side effects, including: fainting, fast/irregular heartbeat, severe dizziness.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using eribulin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: blood/bone marrow problems (such as low red/white blood cells and platelets), kidney problems, liver problems.Eribulin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using eribulin, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using eribulin safely.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Eribulin can make you more likely to get infections or may make current infections worse. Stay away from anyone who has an infection that may easily spread (such as chickenpox, COVID-19, measles, flu). Talk to your doctor if you have been exposed to an infection or for more details.Tell your health care professional that you are using eribulin before having any immunizations/vaccinations. Avoid contact with people who have recently received live vaccines (such as flu vaccine inhaled through the nose).To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially QT prolongation (see above).Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using eribulin. Eribulin may harm an unborn baby. Women using this medication should ask about reliable forms of birth control during treatment and for at least 2 weeks after the last dose. Men using this medication should ask about reliable forms of birth control during treatment and for 14 weeks after the last dose. If you or your partner becomes pregnant, talk to your doctor right away about the risks and benefits of this medication.It is unknown if this medication passes into breast milk. Because of possible risk to the infant, breast-feeding while using this drug and for 2 weeks after treatment is not recommended. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Lab and/or medical tests (such as complete blood counts) should be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule.
STORAGE: Not applicable. This medication is given in a hospital or clinic and will not be stored at home.
Information last revised August 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
